Caplin Point Laboratories share price today

Caplin Point Laboratories Ltd's share price was ₹2,324.85 at the close on 30 October 2026. It has been rising for 21 weeks. That is 1.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,558 and ₹2,845, and at that close it sat 60% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Caplin Point Laboratories Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 3 weeks running.

Over the last 11 years the share price moved +1,032% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), profit up on a year earlier for 11 quarters in a row (every quarter we can compare) and highest quarterly profit in 15 quarters.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹610 crore, +19.6% on a year earlier.

   Why: The latest rise came from US sales nearly tripling.

   Next results: check whether the new sterile lines start adding sales after approvals.

   From the earnings call on 12 Aug 2026.

2. Profit up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter profit was ₹179 crore, +18.5% on a year earlier.

   Why: Profit rose because running costs took a smaller share of sales.

   Next results: check whether gross margin, sales minus direct product costs, stays near 60% as product mix changes.

   From the earnings call on 12 Aug 2026.

3. Highest quarterly profit in 15 quarters

   Profit of ₹179 crore in the June 2026 quarter is the highest of the last 15 quarters.

For April to June 2026 (the quarter ended 30 June 2026), Caplin Point Laboratories reported revenue of ₹610 crore, up 19.6% from ₹510 crore a year earlier, and a profit of ₹179 crore, up 18.5% from ₹151 crore.

Caplin Point Laboratories results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Caplin Point Laboratories' management discussed these results on a call held on 12 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Caplin Point Laboratories closed at ₹2,324.85 on 30 October 2026, up 14.4% from ₹2,032.80 a year earlier (31 October 2025) and up 183.2% over five years. Its highest weekly close since March 2016 was ₹2,845.20 on 28 September 2026.

Caplin Point Laboratories share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 30 October 2026.

30 Oct 2026: Caplin Point Laboratories closed at ₹2,324.85, up 4.6% on the week and down 11.7% on the month. 18 Sep 2026: ex-date for a dividend of ₹4 a share.

Earlier

• Our read, 22 Aug 2026: A LATAM-pharma and US-sterile compounder building regulated-market scale from its own balance sheet, earnings growing steadily while the sterile injectable ramp is the next profit multiplier.
• 12 Aug 2026: Caplin Point Laboratories held its results call for April to June 2026. Management guided: Gross margin expected around 60% through the year.
• Results for April to June 2026: Revenue up 19.6% and profit up 18.5% on a year earlier.
• 29 May 2026: ex-date for an interim dividend of ₹4 a share, record date 30 May 2026.

Our read of the business

Caplin Point has grown profit from 251 crore in FY21 to 650 crore in FY26 with zero debt, funding a 1,000 crore capital spending cycle from operating cash. The US sterile business nearly tripled its own-label revenue year-on-year in April to June 2026, proving the ramp is real.

April to June 2026: 20% revenue growth, 19% profit growth, operating margin stable at 35%, solid delivery against elevated expectations.

Our read after the April to June 2026 results, written 22 August 2026.

Caplin Point Laboratories paid ₹8 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 0.34% at the ₹2,324.85 close on 30 October 2026. The last was a dividend of ₹4 a share, ex-date 18 September 2026.

Caplin Point Laboratories dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Caplin Point Laboratories Ltd paid out 9% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 12 August 2026, Caplin Point Laboratories' management guided: Gross margin expected around 60% through the year.

“Our current challenge is not in the form of dearth of orders but lack of capacities in our two major factories which is CP1 in Pondicherry and the CSL in Gummidipoondi.”CC Partheban, Chairman, on the call for April to June 2026

What management guided

• FY27 profit margin commitment at 25%.
• Cash flow expected to improve from July to September 2026 as inventory additions normalize; government-supply receivables expected by October to December 2026.
• Sterile rollout: Line 7 in 6-7 months; five Phase 3 lines by this time next year; 13 lines visible including oncology; transferred products need 9-10 months for commercial start; three-four more lines potentially by 2029+.
• Amaris expansion to 120 beds for internal BE studies.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 12 August 2026.

Sterile line commissioning slips by more than three quarters, product transfers require 9-10 months for supplements and stability batches before commercial contribution, so a capacity delay compounds into a revenue lag.

Each change stops working if

• : Sterile line commissioning slips by more than three quarters, product transfers require 9-10 months for supplements and stability batches before commercial contribution, so a capacity delay compounds into a revenue lag.
• : LATAM tender participation dries up and private-market penetration stalls because Mexico local manufacturing is not yet economical, removing both the tender and the private-market growth legs simultaneously.
• : Rest-of-world profit before tax margin keeps falling from its current 33%, a continued decline there combined with higher depreciation from new line capitalisations could offset the operating leverage on headline operating margin.
• : A large unplanned acquisition significantly depletes the liquid buffer, changing the risk profile from self-funded to leveraged.

The main risks

• : April to June 2026 operating cash flow/profit of 0.53, the weakest quarterly conversion in recent memory, driven by inventory build and government receivables. ⚠ estimate
• : Rest-of-world profit before tax margin fell from 37.5% to approximately 33% in April to June 2026, generic mix and added marketing costs compressing the LATAM core. ⚠ estimate
• : ROCE structural decline from 45% in FY19 to 25% in FY26, acceptable in a manufacturing scale-up but may compress further before CSL matures. ⚠ estimate

Our read after the April to June 2026 results, written 22 August 2026.

When Caplin Point Laboratories reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Rest-of-world profit before tax margin to stabilize or improve - check for continued generic-mix and marketing-cost pressure.

Caplin Point Laboratories is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

Caplin Point Laboratories Ltd earned ₹179 Cr of net profit in the Jun 2026 quarter, +18.5% on the same quarter a year earlier. That is the 12th quarter in a row of profit growth. Full-year FY26 profit was ₹650 Cr. Over 10 years profit has grown 30.3% a year on average. That is 29.3% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹151 Cr.

For the full year, FY26 profit was ₹650 Cr (+20.1% on the year before).

Why profit moved: revenue changed +19.6% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +19.6% and revenue +15.0%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

FY26-Q4. revenue ₹600 Cr and profit ₹173 Cr as reported.

FY27-Q1. revenue ₹610 Cr and profit ₹179 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Caplin Point Laboratories Ltd reported ₹610 Cr of revenue in the Jun 2026 quarter, +19.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 24.8% a year on average. The last full year, FY26, came in at ₹2,187 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. CSL own-label revenue grew from 14.4 crore to 43.1 crore year-on-year in Q1 FY27, tracking ahead of the 200-crore FY27 full-year goal. The US business grew 26% overall. CSL has 39 of 60-plus approved ANDAs and has 40-plus products in pipeline spanning pre-filled syringes, ophthalmic suspensions and other sterile forms. New lines are commissioning over the next 6-18 months, each unlocking additional ANDA commercial capacity.

The last four reported quarters add to ₹2,287 Cr.

FY26 revenue was ₹2,187 Cr, +12.9% on the year before.

Recent pace: the last four quarters grew +15.0% on average, against 24.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +15.0%, against +14.1% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +19.6%, against +18.6% a year (stabilising).

FY26-Q4. revenue ₹600 Cr and profit ₹173 Cr as reported.

FY27-Q1. revenue ₹610 Cr and profit ₹179 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Caplin Point Laboratories Ltd's operating margin was 35.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Across 13 years it has been between 21.0% and 36.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. OPM has run at 34-35% for six consecutive quarters without dipping below 33%. In Q1 FY27, the EBITDA margin expanded as the operating-expense ratio fell from 25.7% to 23.6% despite gross margin moving with mix. Personnel costs from the hiring phase are already embedded; each incremental revenue rupee contributes at a high marginal rate.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.1 percentage points on the year while gross margin changed −1.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY26-Q4. revenue ₹600 Cr and profit ₹173 Cr as reported.

FY27-Q1. revenue ₹610 Cr and profit ₹179 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Over the last 3 years, 77% of Caplin Point Laboratories Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY26 it brought in ₹523 Cr of operating cash against ₹650 Cr of profit. After ₹197 Cr of spending on assets, ₹326 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 77% of profit came in as cash: the cash cycle got 28 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 28 days longer. The next section looks at where the cash is stuck.

Caplin Point Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 194 days in FY26, up from 166 days in FY21. It spent ₹505 Cr on assets over the last 3 years. Customers take 138 days to pay, and stock sits for 181 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Why this happened. Chile entered with 135 product registrations and 10 million dollars of orders secured for 18 months. Mexico swept all 8 products in a 2-year government tender, has 25 registrations, and has a 4 million dollar near-term sales goal; local manufacturing is under evaluation. The El Salvador supplementary tender is pending decision and could add 10-15% of the original tender volume.

At FY26 sales of ₹2,187 Cr, each day of that cycle ties up about ₹6.0 Cr, so roughly ₹1,162 Cr is tied up in the business at any time.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 181 days. Customers pay about 138 days after that. Suppliers are paid at 125 days. Together that makes the 194-day cycle.

Spending on assets: ₹505 Cr over the last 3 years, against ₹192 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹234 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Caplin Point Laboratories Ltd's P/E is 26.6×, in the middle of its own history: higher than 65% of past readings. Its usual P/E (the middle reading) is 22.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.